GlassScriptPhysician profile
Aaron L Kime
NPI 1568486306
$1,519.33
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2023: $844 · 2024: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.06 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $204.78 | 2023 | Rexulti |
| Abbott Laboratories | $167.29 | 2024 | Proclaim |
| Atricure, INC. | $131.78 | 2024 | |
| Almatica Pharma LLC | $103.08 | 2023 | Loreev Xr, Sertraline Hcl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.28 | 2021 | |
| Scilex Pharmaceuticals INC. | $80.24 | 2021 | |
| Redhill Biopharma INC. | $72.64 | 2021 | |
| Bausch Health US, LLC | $56.65 | 2023 | Aplenzin |
| Collegium Pharmaceutical, INC. | $53.36 | 2021 | |
| Corium, LLC | $50.03 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $45.98 | 2023 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $45.76 | 2023 | Quviviq |
| Pfizer INC. | $34.71 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.42 | 2023 | Hetlioz, Fanapt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.98 | 2023 | Auvelity |
| Virtus Pharmaceuticals LLC | $19.12 | 2021 | |
| Tris Pharma INC | $19.01 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $17.10 | 2023 | Rexulti |
| Alkermes, INC. | $16.07 | 2023 | Lybalvi |
| Si-Bone, INC. | $15.32 | 2021 | |
| Glaxosmithkline, LLC. | $14.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Kime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.